NeurAxis (NASDAQ:NRXS) and GlucoTrack (NASDAQ:GCTK) Head to Head Survey

NeurAxis (NASDAQ:NRXS) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Profitability

This table compares NeurAxis and GlucoTrack’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
GlucoTrack	N/A	-581.98%	-220.10%

Institutional & Insider Ownership

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 8.4% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

NeurAxis has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, GlucoTrack has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Valuation & Earnings

This table compares NeurAxis and GlucoTrack”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28 million	20.66	-$14.63 million	($0.81)	-8.75
GlucoTrack	N/A	N/A	-$19.39 million	($18.04)	-0.02

NeurAxis has higher revenue and earnings than GlucoTrack. NeurAxis is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for NeurAxis and GlucoTrack, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	0	1	0	3.00
GlucoTrack	1	0	0	0	1.00

NeurAxis presently has a consensus target price of $13.00, suggesting a potential upside of 83.36%. Given NeurAxis’ stronger consensus rating and higher possible upside, equities analysts clearly believe NeurAxis is more favorable than GlucoTrack.

Summary

NeurAxis beats GlucoTrack on 10 of the 13 factors compared between the two stocks.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.